# reload+after+2024-01-22 13:43:09.432171
address1§Building C14
address2§4th Floor No. 218, Xinghu Street Suzhou Industrial Park
city§Suzhou
zip§215123
country§China
phone§86 512 8777 3632
website§https://www.adagene.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
fullTimeEmployees§248
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Peter P.  Luo Ph.D.', 'age': 57, 'title': 'Co- Founder, Chairman, CEO and President of R&D', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Man Kin  Tam M.B.A.', 'age': 46, 'title': 'CFO & Director', 'yearBorn': 1977, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jc  Xu M.D., Ph.D.', 'age': 58, 'title': 'Chief Scientific Officer', 'yearBorn': 1965, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ami Celeste Knoefler', 'title': 'Vice President of Investor Relations & Corporate Communications', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ling  Zhou', 'title': 'Head of Human Resources', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Qinghai  Zhao', 'age': 62, 'title': 'Chief Manufacturing Officer', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Yan  Li M.B.A.', 'age': 48, 'title': 'Senior VP of Bioinformatics & Information Technology and Director', 'yearBorn': 1975, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Xiaohong  She', 'age': 56, 'title': 'Senior VP & Head of Clinical Operations', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Guizhong  Liu Ph.D.', 'age': 52, 'title': 'Head of Biology & Pharmacology', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander  Goergen', 'age': 36, 'title': 'VP & Head of Business Development', 'yearBorn': 1987, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.445
priceToSalesTrailing12Months§4.2548018
currency§USD
dateShortInterest§1702598400
forwardEps§-2.01
exchange§NGM
quoteType§EQUITY
shortName§Adagene Inc.
longName§Adagene Inc.
firstTradeDateEpochUtc§1612881000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§62e74ad1-53ab-3c04-9114-3e2ec68862ec
gmtOffSetMilliseconds§-18000000
targetHighPrice§26.0
targetLowPrice§4.6
targetMeanPrice§13.67
targetMedianPrice§12.03
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§3.312
grossMargins§1.0
ebitdaMargins§-1.73321
trailingPegRatio§None
